[Form 4] Anixa Biosciences Inc Insider Trading Activity

Rhea-AI Filing Summary

Anixa Biosciences (ANIX) CEO Amit Kumar reported an insider option exercise. On 10/30/2025, he exercised 200,000 stock options at $2.92 per share (code M), adding common shares.

To cover the exercise price and tax withholding, 169,439 shares were withheld and reported as a disposition at $4.06 (code F). Following these transactions, Kumar beneficially owns 610,486 shares directly. The filing notes no open-market share sales in connection with this exercise.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KUMAR AMIT

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CA 95118

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/30/2025		M		200,000	A	$2.92	779,925	D
Common Stock	10/30/2025		F(1)		169,439	D	$4.06	610,486	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(2)	$2.92	10/30/2025		M			200,000	(3)	02/18/2026	Common Stock	200,000	$0	0	D

Explanation of Responses:

1. The reporting person exercised the stock options at this time due to their upcoming expiration on February 18, 2026. The disposal of shares reported herein represents shares withheld by Anixa Biosciences, Inc. (the "registrant") to (i) cover the exercise price of the stock options and (ii) satisfy tax withholding obligations in connection with the exercise of the stock options. Dr. Kumar did not sell any shares in connection with the exercise of the options.

2. Right-To-Buy, pursuant to a stock option grant dated February 18, 2016.

3. The option vested in 36 consecutive monthly installments beginning on March 31, 2016.

	/s/ Amit Kumar	10/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANIX report?

CEO Amit Kumar exercised 200,000 stock options on 10/30/2025 at $2.92 per share.

Were any shares sold on the market by the ANIX CEO?

No. The filing states that no shares were sold; shares were withheld to cover costs and taxes.

How many shares were withheld for costs and taxes?

The filing reports 169,439 shares were withheld and recorded as a disposition at $4.06.

What is the ANIX CEO’s ownership after the transaction?

Amit Kumar beneficially owns 610,486 shares directly following the reported transactions.

What options were exercised and when did they expire?

Options granted on 02/18/2016 with an exercise price of $2.92 were exercised before their 02/18/2026 expiration.

What Form 4 transaction codes were used in this ANIX filing?

Code M for the option exercise and code F for shares withheld for costs and taxes.